Where The Next Generation of Ocular Delivery Takes Shape
The challenge in Ocular therapies is no longer simply developing the therapy but determining how to get it precisely where it needs to go, keep it there and make treatments practical for patients.
The 5th Ophthalmic Drug Delivery Summit brings together the specialists tackling that challenge across the full development lifecycle. Explore how methods to extend ocular exposure through, progress innovative techniques to progress sustained delivery and sustained-release implants through conventional intravitreal injection.
The program goes beyond individual technologies to examine what it takes to translate innovation into successful products. Hear from Sanofi and Astellas on improving preclinical and clinical translation, Beacon Therapeutics on advancing ocular gene therapy delivery, and Eli Lilly, Genentech and Apellis on the development challenges shaping long-acting therapies.
Expect candid lessons, emerging strategies and cross-functional perspectives spanning delivery, formulation, devices, CMC, clinical development, regulatory strategy and commercialisation.
Engineer Longer-Lasting Therapies
Explore the latest approaches to extending ocular exposure and reducing the burden of frequent treatment
Rethink How Therapies Reach the Retina
Compare intravitreal, suprachoroidal, topical and implantable approaches, including emerging strategies for gene and cell therapies
Close The Translation Gap
Learn how Sanofi, Astellas, Apellis and others are approaching predictive models, biomarkers, endpoints and clinical translation
Design For Patients From Day One
Discover why formulation, device, human factors, manufacturing and clinical considerations need to work together from the earliest stages
Prepare For The Next Wave Of Delivery
Look ahead to non-viral vectors, ASOs, siRNA, AI-powered delivery, precision exposure and digital-twin approaches
Explore the Full Event Guide
- 3 days of cutting-edge ophthalmic drug delivery content
- 3 interactive pre-conference workshops
- Long-acting, gene & cell therapy, topical, implantable & suprachoroidal delivery
- Insights from leaders at Eli Lilly, Genentech, Sanofi, Astellas & more
- Speed networking, roundtables, panels and poster sessions designed for meaningful industry connection
Attending Companies Include
Explore The Latest Delivery Innovations
See how long acting, suprachoroidal, implantable and topical technologies are changing the possibilities for ocular therapy to identify approaches that could improve durability, efficacy and patient outcomes.
Meet Experts Shaping the Field
Connect with the scientists, clinicians, developers and technology leaders solving the industry's toughest delivery challenges to build relationships that can accelerate your next program.
Move Your Program Forward
Take practical insights from toxicology and translation through to regulatory, manufacturing and clinical development, helping you de-risk development and accelerate your path to the clinic .